Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1989-12-01
1991-10-01
Lee, Lester L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 19, 530330, 530331, 548953, A61K 3700
Patent
active
050533924
ABSTRACT:
Disclosed are novel amino acid derivatives of the formula: ##STR1## wherein X is H, amidino or ##STR2## Y is H, amino or ##STR3## Z is ##STR4## OR.sub.1 or a naturally occurring L-amino acid, bounded to the carbon atom at the .alpha.-amino position;
REFERENCES:
patent: 4683291 (1987-07-01), Zimmerman et al.
Chou et al., "Prediction of Protein Conformation", Biochemistry, vol. 13, No. 2 (1974), pp. 222-224.
Pierschbacher et al., "Influence of Sterochemistry of the Sequence", J. Biol. Chem., vol. 262, No. 86, pp. 17294-17298 (1987).
Ginsberg et al.; "Inhibition of Fibronectin Binding to Platelets by Proteolytic Fragments and Synthetic Peptides Which Support Fibroblast Adhesion"; The Journal of Biological Chemistry, vol. 260, No. 7, Apr. 10, 1985; pp. 3931-3936.
Gartner et al.; "The Tetrapeptide Analogue of the Cell Attachment Site of Fibronectin Inhibits Platelet Aggregation and Fibrinogen Binding to Activated Platelets", The Journal of Biological Chemistry; vol. 260, No. 22, Oct. 5, 1985; pp. 11891-11894.
Haverstick et al., "Inhibition of Platelet Adhesion to Fibronectin, Fibrinogen, and vWF Substrates by a Synthetic Tetrapeptide Derived From the Cell-Binding Domain of Fibronectin"; Blood, vol. 66, No. 4 (Oct.), 1985: pp. 946-952.
Plow et al., "Inhibition of Fibrinogen Binding to Human Platelets by the Tetrapeptide glycyl-L-prolyl-L-arginyl-L-proline"; Proc. Natl. Acad. Sci. U.S.A., vol. 79, pp. 3711-3715, Jun. 1982.
Plow et al., "The Effect of Arg-Gly-Asp-Containing Peptides on Fibrinogen and von Willebrand Factor Binding to Platelets"; Proc. Natl. Acad. Sci. U.S.A., vol. 82, pp. 8057-8061, Dec. 1985.
Santoro et al. ; "Competition for Related but Nonidentical Binding Sites on the Glycoprotein IIb-IIIa Complex by Peptides Derived from Platelet Adhesive Proteins"; Cell, vol. 48, 867-873, Mar. 13, 1987.
Ruggeri et al.; "Inhibition of Platelet Function with Synthetic Peptides Designed to be High-Affinity Antagonists of Fibrinogen Binding to Platelets"; Proc. Natl. Acad. Sci. U.S.A.; vol. 83, pp. 5708-5712, Aug. 1986.
Ruoslahti et al. ; "Arg-Gly-Asp: A Versatile Cell Recognition Signal", Cell, vol. 44, 517-518, Feb. 28, 1986.
Klein Scott I.
Molino Bruce F.
Balogh Imre (Jim)
Kraus E. J.
Lee Lester L.
Nicholson James A.
Rhone-Poulenc Rorer Pharmaceuticals Inc.
LandOfFree
Novel arginine, glycine, aspartic acid derivatives as platelet-a does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel arginine, glycine, aspartic acid derivatives as platelet-a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel arginine, glycine, aspartic acid derivatives as platelet-a will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1755071